An In-Depth Look at Cyclo Therapeutics Inc’s (CYTH) Stock Performance

In the past week, CYTH stock has gone up by 2.10%, with a monthly decline of -9.32% and a quarterly plunge of -8.18%. The volatility ratio for the week is 12.29%, and the volatility levels for the last 30 days are 10.22% for Cyclo Therapeutics Inc The simple moving average for the past 20 days is -5.65% for CYTH’s stock, with a -3.35% simple moving average for the past 200 days.

Is It Worth Investing in Cyclo Therapeutics Inc (NASDAQ: CYTH) Right Now?

The 36-month beta value for CYTH is also noteworthy at -0.15. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for CYTH is 12.63M, and at present, short sellers hold a 0.89% of that float. The average trading volume of CYTH on April 03, 2024 was 101.50K shares.

CYTH) stock’s latest price update

Cyclo Therapeutics Inc (NASDAQ: CYTH) has experienced a rise in its stock price by 7.35 compared to its previous closing price of 1.36. However, the company has seen a gain of 2.10% in its stock price over the last five trading days. Business Wire reported 2023-10-05 that GAINESVILLE, Fla.–(BUSINESS WIRE)–Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer and Joshua Fine, Chief Financial Officer of Cyclo Therapeutics will present at the 8th Annual Dawson James Conference being held in Jupiter, FL on Thursday,.

CYTH Trading at -11.92% from the 50-Day Moving Average

After a stumble in the market that brought CYTH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.19% of loss for the given period.

Volatility was left at 10.22%, however, over the last 30 days, the volatility rate increased by 12.29%, as shares sank -13.61% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -9.88% lower at present.

During the last 5 trading sessions, CYTH rose by +2.10%, which changed the moving average for the period of 200-days by -30.48% in comparison to the 20-day moving average, which settled at $1.5360. In addition, Cyclo Therapeutics Inc saw -8.18% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CYTH starting from Rafael Holdings, Inc., who purchase 4,000,000 shares at the price of $1.25 back on Aug 01 ’23. After this action, Rafael Holdings, Inc. now owns 6,514,970 shares of Cyclo Therapeutics Inc, valued at $5,000,000 using the latest closing price.

FINE N SCOTT, the Chief Executive Officer of Cyclo Therapeutics Inc, purchase 299,402 shares at $0.71 during a trade that took place back on Apr 20 ’23, which means that FINE N SCOTT is holding 444,402 shares at $212,575 based on the most recent closing price.

Stock Fundamentals for CYTH

Current profitability levels for the company are sitting at:

  • -18.63 for the present operating margin
  • 0.12 for the gross margin

The net margin for Cyclo Therapeutics Inc stands at -18.63. The total capital return value is set at -4.2. Equity return is now at value -730.48, with -229.72 for asset returns.

Based on Cyclo Therapeutics Inc (CYTH), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -15.67. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is 426596.89.

Currently, EBITDA for the company is -20.03 million with net debt to EBITDA at 0.41. When we switch over and look at the enterprise to sales, we see a ratio of 31.32. The receivables turnover for the company is 8.8for trailing twelve months and the total asset turnover is 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.45.

Conclusion

In summary, Cyclo Therapeutics Inc (CYTH) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts